InvestorsHub Logo
Followers 118
Posts 19193
Boards Moderated 0
Alias Born 08/27/2005

Re: Dante Fantasia post# 285302

Thursday, 03/08/2018 9:09:36 AM

Thursday, March 08, 2018 9:09:36 AM

Post# of 403483

To me, that sounds like NH is going for the new one. Could I be wrong? Absolutely. Drug A per Nasdaq's post also looks viable w/regards to meeting the FDA stated criteria; the T-max outlier was equal to that of Roxy, and rest within bounds. I agree however, NH should have not made it so unclear--he could have simply stated "we are continuing to progress on our efforts for SequestOx resubmission" and left it at that..




How is it you see mixed signals? I think NH was very clear here. The pilot was set up for the SequestOx reformulation. Elite happened to have a new
formulation which doesn't use naltrexone and decided to pilot this as well.

How could Elite be going with this new formulation when there are no patents YET! When testing has not been completed on this formulation yet.

NH even said that this formulation in the initial stages. Do you know how long it would take for Elite to switch gears to another formulation? Could be a couple of years.

The ONLY signal I see is SequestOx reformulated. Right now it is the
NDA formulation in the crosshairs.

There are not mixed signals.... only a POTENTIAL new formulation that shows lots of promise for a future IR ADF.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News